Insulet Corp Stock Price, News & Analysis

Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami. The presentation is scheduled for June 10, 2025, at 9:20 a.m. ET. The company will provide a live audio webcast accessible through their investor relations website.

Insulet specializes in the Omnipod Insulin Management System, offering a unique tubeless disposable Pod that provides three days of continuous insulin delivery without needles. Their flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitors and can be controlled via smartphone in the U.S. or through the Omnipod 5 Controller.

Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, has released its 2024 Sustainability Report highlighting significant ESG achievements. The company met 11% of its global electricity needs with renewable energy and installed over 5,700 solar panels at its Malaysia facility, covering 21% of the facility's electricity needs. The facility is designed to achieve GBI and LEED Silver certifications.

Key accomplishments include collecting 7.4 million Pods through global takeback programs and expanding access to Omnipod 5 internationally through integration with Abbott's FreeStyle Libre 2 Plus and Dexcom G7 sensors. The company also launched the Omnipod 5 App for iPhone and introduced "Insulet for Good," a global corporate giving program that exceeded employee engagement goals.

Insulet (NASDAQ: PODD) reported strong Q1 2025 financial results with revenue increasing 29% year-over-year to $569.0 million. The company's core Omnipod business generated $554.1 million in revenue, up 28%. U.S. Omnipod revenue grew 26.4% to $401.7 million, while International Omnipod revenue increased 32.2% to $152.4 million. Gross margin improved to 71.9%, up 240 basis points. The company reported net income of $35.4 million ($0.50 per diluted share). Key operational highlights include the expansion of Omnipod 5 to four new countries (Australia, Belgium, Canada, and Switzerland), positive RADIANT trial results showing improved glucose control, and a new $125 million stock repurchase program. The company raised its full-year 2025 guidance, now expecting total revenue growth of 19-22% and gross margin of ~71%.

Insulet (NASDAQ: PODD) has appointed Ashley McEvoy as President and CEO, effective immediately, replacing Jim Hollingshead who will cease employment on April 28, 2025. McEvoy brings nearly three decades of healthcare leadership experience, previously serving as Executive Vice President and Worldwide Chairman of Johnson & Johnson's MedTech business.

Under Hollingshead's leadership, Insulet launched Omnipod 5, achieving market leadership in type 1 diabetes in the U.S. and Europe, and became first-to-market in Automated Insulin Delivery for type 2 diabetes in the U.S. The company expects to exceed its Q1 2025 revenue guidance and plans to raise full-year 2025 guidance, with details to be announced on May 8, 2025.

Due to the leadership transition, Insulet has postponed its previously scheduled June 5, 2025 Investor Day to a later date.

Insulet (NASDAQ: PODD), the global leader in tubeless insulin pump technology, will release its first quarter 2025 financial results on May 8, 2025, after market close. Management will host a conference call at 4:30 p.m. (Eastern Time).

The company specializes in the Omnipod Insulin Management System, offering a tubeless disposable Pod that provides up to three days of continuous insulin delivery. Their flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitors and can be controlled via smartphone in the U.S. or through the Omnipod 5 Controller.

Insulet (NASDAQ: PODD) announced significant results from its RADIANT study of the Omnipod 5 Automated Insulin Delivery System. The multinational randomized controlled trial evaluated direct transition from multiple daily injections (MDI) to automated insulin delivery in type 1 diabetes patients.

Key findings from the 188-participant study showed:

• Average HbA1c reduction of -0.8% compared to MDI with continuous glucose monitor
• Additional 5.4 hours per day with glucose levels in target range (70-180mg/dL)
• Final average time in range improved to 65% from 39% baseline
• No life-threatening events or severe hypoglycemia reported

The study, conducted across 19 clinical centers in France, UK, and Belgium, included participants aged 4-70 years with HbA1c levels of 7.5% to 11%. Patients using Omnipod 5 with initial HbA1c above 8.0% showed even greater improvement of 1.0% compared to MDI plus CGM.

Insulet (NASDAQ: PODD) has announced the pricing of $450 million in senior unsecured notes due 2033. The notes will carry a 6.50% annual interest rate with maturity on April 1, 2033. The private placement is expected to close on March 20, 2025.

The company estimates net proceeds of approximately $444.4 million after discounts and before offering expenses. The funds will be used to finance the redemption or repurchase of existing 0.375% Convertible Senior Notes due 2026, cover related fees and expenses, and for general corporate purposes. The notes are being offered exclusively to qualified institutional buyers under Rule 144A and non-U.S. persons outside the United States under Regulation S.

Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, has announced plans to offer $450 million in senior unsecured notes due 2033 through a private placement. The company intends to use the proceeds, along with cash on hand, to manage its existing 0.375% Convertible Senior Notes due 2026.

Additionally, Insulet plans to amend its Credit Agreement to extend its revolving credit facility maturity from 2028 to 2030 and increase revolving credit commitments by up to $200 million, potentially reaching aggregate commitments of up to $500 million. Both transactions are subject to market conditions and may not proceed as described.

The Notes will be exclusively offered to qualified institutional buyers under Rule 144A and non-U.S. persons outside the United States under Regulation S of the Securities Act of 1933.

Insulet (NASDAQ: PODD) has announced the expansion of its Omnipod 5 Automated Insulin Delivery System to four new international markets. The system is now commercially available in Australia with Dexcom G6 and G7 compatibility, and will soon launch in Belgium, Canada, and Switzerland.

The tubeless insulin delivery system features SmartAdjust™ technology that automatically adjusts insulin delivery every five minutes. In Australia, plans are underway to add Abbott's FreeStyle Libre® 2 Plus compatibility. Belgium will have access to both Abbott's FreeStyle Libre 2 Plus and Dexcom G6/G7 integrations. Canada and Switzerland launches are scheduled for spring, with varying sensor compatibilities.

Additionally, Insulet plans to expand to five more markets including Israel, Saudi Arabia, UAE, Qatar, and Kuwait, with timing to be announced. The company recently added Dexcom G7 integration for Omnipod 5 users in the UK and Netherlands.